Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study.

ABSTRACT:

SUBMITTER: Basso-Valentina F 

PROVIDER: S-EPMC12183328 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature